Federal Court of Appeal dismisses appeal of first trial decision under the amended PMNOC Regulations

Smart & Biggar
Contact

On November 3, 2020, the Federal Court of Appeal heard and dismissed the appeal of the first trial decision under the amended Patented Medicines (Notice of Compliance) Regulations: Amgen v Pfizer, 2020 FCA 188. Amgen had appealed the trial decision, previously reported here, which held obvious the asserted claims of Canadian Patent No. 1,341,537, relating to filgrastim (Amgen’s NEUPOGEN and Pfizer’s biosimilar product NIVESTYM).

The Court of Appeal found that the trial judge had a correct understanding of the legal factors to be considered and applied in the test for obviousness, which is flexible and must be applied contextually to the facts and circumstances of each claim. The Court of Appeal further held that the trial judge had not committed any palpable and overriding error in concluding as he had, and that the Court of Appeal would have reached the same result if it were to apply the legal test for obviousness to the evidence as if it were a court of first instance.

Any appeal by Amgen would require the grant of leave by the Supreme Court of Canada.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar
Contact
more
less

Smart & Biggar on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.